Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing

Leukemia. 2020 Feb;34(2):662-666. doi: 10.1038/s41375-019-0549-y. Epub 2019 Sep 12.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Cell Line
  • Humans
  • Infant
  • Intracellular Signaling Peptides and Proteins / genetics*
  • Leukemia, Myelomonocytic, Juvenile / drug therapy*
  • Leukemia, Myelomonocytic, Juvenile / genetics*
  • Male
  • Mice
  • Microfilament Proteins / genetics*
  • Mutation / genetics
  • Sequence Analysis, RNA / methods
  • Sorafenib / therapeutic use*
  • Whole Exome Sequencing / methods
  • fms-Like Tyrosine Kinase 3 / genetics*

Substances

  • Antineoplastic Agents
  • CCDC88C protein, human
  • Intracellular Signaling Peptides and Proteins
  • Microfilament Proteins
  • Sorafenib
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3